Acquistions (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of Research and Development Assets Acquired Other than Through Business Combination

The following table and narrative summarizes our asset acquisition during the six months ended June 30, 2017. There was no asset acquisition which resulted in acquired IPR&D expense during the six months ended June 30, 2016.



Counterparty	Compound(s) or Therapy	Acquisition Month	Phase of Development ⁽¹⁾	Acquired IPR&D Expense
CoLucid	Oral therapy for the acute treatment of migraine - lasmiditan	March 2017	Phase III	$	857.6

⁽¹⁾ The phase of development presented is as of the date of the arrangement.

Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at January 3, 2017
Inventories	$	119.3
Acquired in-process research and development	6.0
Marketed products ⁽¹⁾	374.0
Property and equipment	149.8
Other assets and liabilities - net	(2.8		)
Total identifiable net assets	646.3
Goodwill ⁽²⁾	235.8
Total consideration transferred - net of cash acquired	$	882.1

⁽¹⁾ These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 10 years.

⁽²⁾ The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of BIVIVP with our legacy animal health business, future unidentified projects and products, and the assembled workforce of BIVIVP. We anticipate that the goodwill associated with this acquisition will be deductible for tax purposes.